712 related articles for article (PubMed ID: 28279838)
1. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
[TBL] [Abstract][Full Text] [Related]
2. Modulation of sphingosine-1-phosphate in ulcerative colitis.
Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
[No Abstract] [Full Text] [Related]
3. [The place of sphingosine-1-phosphate modulators in the therapy of inflammatory bowel diseases].
Szymaszkiewicz K; Szymaszkiewicz A; Fichna J
Postepy Biochem; 2020 Mar; 66(1):42-48. PubMed ID: 33320478
[TBL] [Abstract][Full Text] [Related]
4. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease.
Verstockt B; Vetrano S; Salas A; Nayeri S; Duijvestein M; Vande Casteele N;
Nat Rev Gastroenterol Hepatol; 2022 Jun; 19(6):351-366. PubMed ID: 35165437
[TBL] [Abstract][Full Text] [Related]
6. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
Scott FL; Clemons B; Brooks J; Brahmachary E; Powell R; Dedman H; Desale HG; Timony GA; Martinborough E; Rosen H; Roberts E; Boehm MF; Peach RJ
Br J Pharmacol; 2016 Jun; 173(11):1778-92. PubMed ID: 26990079
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease.
Nielsen OH; Li Y; Johansson-Lindbom B; Coskun M
Trends Mol Med; 2017 Apr; 23(4):362-374. PubMed ID: 28283249
[TBL] [Abstract][Full Text] [Related]
8. Innovations in Oral Therapies for Inflammatory Bowel Disease.
Ma C; Battat R; Dulai PS; Parker CE; Sandborn WJ; Feagan BG; Jairath V
Drugs; 2019 Aug; 79(12):1321-1335. PubMed ID: 31317509
[TBL] [Abstract][Full Text] [Related]
9. Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.
Selkirk JV; Bortolato A; Yan YG; Ching N; Hargreaves R
Front Pharmacol; 2022; 13():892097. PubMed ID: 35784713
[TBL] [Abstract][Full Text] [Related]
10. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
[TBL] [Abstract][Full Text] [Related]
11. Etrasimod: First Approval.
Shirley M
Drugs; 2024 Feb; 84(2):247-254. PubMed ID: 38388871
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases.
Tourkochristou E; Mouzaki A; Triantos C
World J Gastroenterol; 2023 Jan; 29(1):110-125. PubMed ID: 36683721
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine-1-phosphate (S1P) signaling regulates the production of intestinal IgA and its potential role in the pathogenesis of canine inflammatory bowel disease.
Nakazawa M; Maeda S; Yokoyama N; Nakagawa T; Yonezawa T; Ohno K; Matsuki N
J Vet Med Sci; 2019 Sep; 81(9):1249-1258. PubMed ID: 31341112
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.
Bencardino S; D'Amico F; Faggiani I; Bernardi F; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S
J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568417
[TBL] [Abstract][Full Text] [Related]
15. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
Chew WS; Wang W; Herr DR
Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease.
Choden T; Cohen NA; Rubin DT
Gastroenterol Hepatol (N Y); 2022 May; 18(5):265-271. PubMed ID: 36397756
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation.
Karuppuchamy T; Tyler CJ; Lundborg LR; Pérez-Jeldres T; Kimball AK; Clambey ET; Jedlicka P; Rivera-Nieves J
Inflamm Bowel Dis; 2020 Jan; 26(2):216-228. PubMed ID: 31807751
[TBL] [Abstract][Full Text] [Related]
18. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine.
Dal Buono A; Gabbiadini R; Alfarone L; Solitano V; Repici A; Vetrano S; Spinelli A; Armuzzi A
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885040
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications.
Spampinato SF; Sortino MA; Salomone S
Adv Pharmacol; 2022; 94():95-139. PubMed ID: 35659378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
